Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

 NEWS 1   Web Page for STN Seminar Schedule - N. America
 NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
                  minutes
 NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
                  (CS) field
 NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
 NEWS 5 AUG 24 CA/CAplus enhanced with legal status information for
                  U.S. patents
 NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
                  CAS REGISTRY
 NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
                  thesaurus

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS   STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN   Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement. This agreement limits use to scientific research. Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:10:32 ON 19 OCT 2009

=> file registry
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   0.22   0.22

FILE 'REGISTRY' ENTERED AT 16:10:45 ON 19 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 OCT 2009 HIGHEST RN 1188905-91-0
DICTIONARY FILE UPDATES: 18 OCT 2009 HIGHEST RN 1188905-91-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s dmxaa
L1   3 DMXAA

=> d l1 1-3

L1   ANSWER 1 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN
RN   853799-58-3 REGISTRY
ED   Entered STN: 05 Jul 2005
CN   9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-, mixt. with
     2-[(2,6-dichlorophenyl)amino]benzeneacetic acid (9CI) (CA INDEX NAME)
OTHER NAMES:
CN   DMXAA-diclofenac mixture
MF   C17 H14 O4 . C14 H11 Cl2 N O2
CI   MXS
SR   CA
LC   STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

     CM   1

     CRN 117570-53-3
     CMF C17 H14 O4



     CM   2

     CRN 15307-86-5
     CMF C14 H11 Cl2 N O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN
RN 129095-08-5 REGISTRY
ED Entered STN: 31 Aug 1990
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-, sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-, sodium salt (9CI)
OTHER NAMES:
CN DMXAA sodium salt
MF C17 H14 O4 . Na
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, IMSPATENTS, IMSRESEARCH, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (117570-53-3)



6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN
RN 117570-53-3 REGISTRY
ED Entered STN: 18 Nov 1988
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)
OTHER NAMES:
CN 5,6-Dimethyl-9-oxo-9H-xanthen-4-ylacetic acid
CN 5,6-Dimethylxanthenone-4-acetic acid
CN AS 1404
CN ASA 404
CN DMXAA
CN NSC 640488
CN Vadimezan
MF C17 H14 O4
CI COM
SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, CA,
CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, EMBASE, IMSPATENTS,
IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE,
TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

196 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
196 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s gemcitabine
L2 11 GEMCITABINE

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.33	17.55

FILE 'CAPLUS' ENTERED AT 16:11:09 ON 19 OCT 2009

FILE COVERS 1907 - 19 Oct 2009 VOL 151 ISS 17
FILE LAST UPDATED: 18 Oct 2009 (20091018/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

substance identification.

```
=> s l1
L3         197 L1

=> s l2
L4        5378 L2

=> s l1 and l2
           197 L1
          5378 L2
L5           6 L1 AND L2

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6            6 DUP REM L5 (0 DUPLICATES REMOVED)

=> d l6 1-6 ibib abs

L6   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2009:739059  CAPLUS
DOCUMENT NUMBER:         151:86657
TITLE:                   Combinations of therapeutic agents comprising vascular
                         disrupting agent such as
                         5,6-dimethylxanthenone-4-acetic acid, for treating
                         cancer
INVENTOR(S):             Evans, Dean Brent; Jacques, Christian J.
PATENT ASSIGNEE(S):      Novartis A.-G., Switz.
SOURCE:                  PCT Int. Appl., 57pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
     WO 2009076170        A2    20090618    WO 2008-US85535        20081204
     WO 2009076170        A3    20090730
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:                       US 2007-13335P      P  20071213
AB   The invention relates to a combination comprising vascular disrupting
     agent (VDA), such as 5,6-dimethylxanthenone-4-acetic acid or a
     pharmaceutically acceptable salt, ester or prodrug thereof; and one or
     more pharmaceutically active agents; pharmaceutical compns. comprising
     said combination; methods of treatment comprising said combination;
     processes for making said combination; and a com. package comprising said
     combination.  Thus, the effects of 5,6-dimethylxanthenone-4-acetic acid
     (Compound A), trastuzumab and paclitaxel are evaluated for their antitumor
     activity using the BT-474 human breast ductal carcinoma xenograft model;
     the data shows that Compound A at 20 mg/kg given i.v. on days 1, 5 and 9 is
```

able to produce inhibition of tumor growth; paclitaxel combined with trastuzumab is also active resulting in a combination effect; when Compound A at 20 mg/kg is combined with paclitaxel and trastuzumab, increased activity is apparent resulting in tumor regressions; using the Clark Combination Index method, synergy is indicated; the tolerability of the triple combinations is no worse than that observed when Compound A is dosed alone.

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1250046 CAPLUS
DOCUMENT NUMBER: 149:448110
TITLE: Preparation of Iso CA-4 and analogs as potent cytotoxic agents and inhibitors of polymerization of tubulin
INVENTOR(S): Alami, Mouad; Brion, Jean-Daniel; Provot, Olivier; Peyrat, Jean-Francois; Messaoudi, Samir; Hamze, Abdallah; Giraud, Anne; Bignon, Jerome; Bakala, Joanna; Liu, Jian-Miao
PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique, Fr.
SOURCE: PCT Int. Appl., 78pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008122620	A1	20081016	WO 2008-EP54118	20080404
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2914640	A1	20081010	FR 2007-54280	20070404
PRIORITY APPLN. INFO.:			FR 2007-54280 A	20070404
OTHER SOURCE(S):	MARPAT 149:448110			

GI



AB Isocombretastatin A-4 and analogs I [R1, R2, R3 = methoxy (possibly substituted by one or more fluorine atoms); R5 = R6 = hydrogen or fluorine; A = ring chosen from (un)substiututed aryls and heteroaryls].

The process for the preparation of I comprises: (a) reaction of acetophenone derivative II with an organometallic compound, A-M [M = alkali metal or earth alkaline metal substituted with a halogen]; and (b) reaction of the resulting phenylethanol derivative III with an acid to form I. Thus, Iso-CA-4 [I; A = C6H3OH-3-OMe-4, R1 = R2 = R3 = OMe, R4 = R5 = R6 = H (IV)] was prepared from 3,4,5-trimethoxyacetophenone (II; R1 = R2 = R3 = OMe, R4 = R5 = R6 = H) via reaction in PhMe with tert-butyl(5-lithio-2-methoxyphenoxy)dimethylsilane [prepared from tert-butyl(5-iodo-2-methoxyphenoxy)dimethylsilane via lithiation with Me3CLi in hexane], dehydration of III with p-toluenesulfonic acid in CH2Cl2, and desilylation with K2CO3 in MeOH. The cytotoxic activity of IV was determined [IC50 = 2-4 nM vs. HCT116; IC50 = 5 nM vs. K562 cells; IC50 = 2 nM vs. B16F10 cells; IC50 = 8 nM vs. U87 cells; IC50 = 8 nM vs. A549 cells; IC50 = 4.5 nM vs. M435 cells; IC50 = 4 nM vs. M231 cells; IC50 = 2.2 μM vs tubulin polymerization].

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:473431 CAPLUS

DOCUMENT NUMBER: 148:463206

TITLE: oncolytic viruses and antiangiogenic agents in the treatment of cancer

INVENTOR(S): Karrasch, Matthias; Mescheder, Axel

PATENT ASSIGNEE(S): Medigene AG, Germany

SOURCE: PCT Int. Appl., 69pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008043576	A1	20080417	WO 2007-EP8930	20071015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2073823	A1	20090701	EP 2007-819001	20071015
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: US 2006-851598P P 20061013
WO 2007-EP8930 W 20071015

AB The invention relates to a combination of at least one oncolytic virus and at least one antiangiogenic agent and to the use of this combination in tumor therapy. Intraarterial infusions of oncolytic virus NV1020 to a patient with progressive metastatic colorectal adenocarcinoma followed by CPT-11 plus cetuximab resulted in stabilization of the disease at 6 mo post treatment.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:984120 CAPLUS
DOCUMENT NUMBER: 143:279360
TITLE: Methods of detecting CD133 antigen (AC133) expression level and use as biomarker for human cancer diagnosis and therapy monitor
INVENTOR(S): Penning, Maarten Tjerk; Van den Broek, Sebastiaan Johannes Jacobus; Voest, Emile Eugene; Beerepoot, Laurens Victor; Mehra, Niven
PATENT ASSIGNEE(S): Primagen Holding B. V., Neth.; UMC Utrecht Holding B. V.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
EP 1725679	A1	20061129	EP 2005-710924	20050302
EP 1725679	B1	20090603		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 432997	T	20090615	AT 2005-710924	20050302
US 20070077578	A1	20070405	US 2006-514345	20060831
US 20090098563	A1	20090416	US 2008-284203	20080919

PRIORITY APPLN. INFO.:

EP 2004-75686	A	20040302
US 2004-549450P	P	20040302
EP 2005-710924	A	20050302
WO 2005-NL155	W	20050302
US 2006-514345	B1	20060831

AB This invention provides methods of detecting CD133 antigen (AC133) expression level and use as a biomarker for human cancer diagnosis and therapy monitor. Blood anal. including number of circulating endothelial cells and expression levels of human genes AC133 (CD133), EST032 and U1A evaluated by NASBA anal., were determined prior to and during chemotherapy using drugs such as angiostatin or PrimMed01, gemcitabine, and cisplatin, for a wide range of human tumor types. A use of a nucleic acid mol. comprising at least part of a sequence of AC133 or an analog thereof for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid mol.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:975665 CAPLUS
DOCUMENT NUMBER: 143:264929
TITLE: Methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases
INVENTOR(S): Penning, Maarten Tjerk; Beerepoot, Laurens Victor; Van Den Broek, Sebastiaan Johannes Jacobus; Mehra, Niven; Voest, Emile Eugene
PATENT ASSIGNEE(S): Primagen Holding B.V., Neth.; UMC Utrecht Holding B.V.
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1725679	A1	20061129	EP 2005-710924	20050302
EP 1725679	B1	20090603		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 432997	T	20090615	AT 2005-710924	20050302

PRIORITY APPLN. INFO.:		
EP 2004-75686	A	20040302
US 2004-549450P	P	20040302
WO 2005-NL155	W	20050302

AB The invention provides methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases. AC133 antigen mRNA may be quantitated by PCR, RT-PCR, NASBA, SDA, TMA, bDNA or rolling circle amplification. Diseases include cancer and heart disease, high blood pressure, ischemia, stroke, psoriasis, Crohn's disease, rheumatoid arthritis, endometriosis, atherosclerosis, obesity, diabetes mellitus, diabetic retinopathy, macular degeneration, Alzheimer's disease, Peutz Jegher's syndrome, multiple sclerosis, systemic lupus erythematosus, Wegener's granulomatosis, vasculitis, sickle cell disease, thalassemia and angina.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:202462 CAPLUS
DOCUMENT NUMBER: 138:226761
TITLE: Synergistic anticancer combinations containing

5,6-dimethylxanthenone-4-acetic acid

INVENTOR(S): Wilson, William Robert; Siim, Bronwyn Gae

PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK

SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020259	A2	20030313	WO 2002-GB4025	20020903
WO 2003020259	A3	20030417		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2458459	A1	20030313	CA 2002-2458459	20020903
AU 2002324143	A1	20030318	AU 2002-324143	20020903
AU 2002324143	B2	20070913		
EP 1423105	A2	20040602	EP 2002-758562	20020903
EP 1423105	B1	20081203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012258	A	20041019	BR 2002-12258	20020903
JP 2005509599	T	20050414	JP 2003-524567	20020903
CN 1708296	A	20051214	CN 2002-817257	20020903
NZ 531045	A	20060831	NZ 2002-531045	20020903
EP 1759694	A2	20070307	EP 2006-77049	20020903
EP 1759694	A3	20090218		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI				
NZ 546573	A	20070531	NZ 2002-546573	20020903
CN 1994287	A	20070711	CN 2006-10151393	20020903
NZ 554093	A	20080731	NZ 2002-554093	20020903
AT 415963	T	20081215	AT 2002-758562	20020903
ES 2321283	T3	20090604	ES 2002-758562	20020903
NO 2004000591	A	20040430	NO 2004-591	20040210
ZA 2004001078	A	20050415	ZA 2004-1078	20040210
US 20040204480	A1	20041014	US 2004-790943	20040302
MX 2004002004	A	20050217	MX 2004-2004	20040302
IN 2004CN00684	A	20060113	IN 2004-CN684	20040402
AU 2007202083	A1	20070531	AU 2007-202083	20070509
AU 2007202083	B2	20090820		
US 20080070847	A1	20080320	US 2007-830650	20070730
US 20080070848	A1	20080320	US 2007-830659	20070730
US 20080070886	A1	20080320	US 2007-830668	20070730
US 20080070849	A1	20080320	US 2007-830677	20070730
IN 2008CN02044	A	20090911	IN 2008-CN2044	20080424
AU 2009202760	A1	20090730	AU 2009-202760	20090708

PRIORITY APPLN. INFO.:

GB 2001-21285	A	20010903
AU 2002-324143	A3	20020903
CN 2002-817257	A3	20020903
EP 2002-758562	A3	20020903
WO 2002-GB4025	W	20020903

US 2004-790943	A1	20040302
IN 2004-CN684	A3	20040402
AU 2007-202083	A3	20070509

AB The present invention relates to synergistic combinations of the 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compds., Vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have antitumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compds. containing the combinations. The antitumor activity and host toxicity of DMXAA/cytotoxic drug combinations was assessed by varying the dose of chemotherapeutic drug up to the toxicity limit, with co-administration of a fixed DMXAA dose (80 μmol/kg, ca. 80% of MTD), and evaluating subsequent tumor growth delay. Of the 7 drugs investigated, 4 (doxorubicin, 5-fluorouracil, cyclophosphamide and cisplatin) had appreciable activity against this tumor as indicated by dose-response relationships providing significant slopes by linear regression, and highly significant growth delays of 10 days at their MTDs.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file medline embase biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.00	36.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.92	-4.92

FILE 'MEDLINE' ENTERED AT 16:12:08 ON 19 OCT 2009

FILE 'EMBASE' ENTERED AT 16:12:08 ON 19 OCT 2009

FILE 'BIOSIS' ENTERED AT 16:12:08 ON 19 OCT 2009

=> s l1<chem>

SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.21	39.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.92

FILE 'REGISTRY' ENTERED AT 16:12:14 ON 19 OCT 2009

```
SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L1 1- CHEM
L7          SEL L1 1- CHEM :      12 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      15.08      54.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.92

FILE 'MEDLINE' ENTERED AT 16:12:14 ON 19 OCT 2009

FILE 'EMBASE' ENTERED AT 16:12:14 ON 19 OCT 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:12:14 ON 19 OCT 2009
Copyright (c) 2009 The Thomson Corporation

S L7
L8          661 L7

=> s l8 and (?cancer? or ?tumor? or ?tumour? or ?neoplasm?)
L9          630 L8 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)

=> s l9 and pd<20020903
   2 FILES SEARCHED...
L10         255 L9 AND PD<20020903

=> s l10 and (potentiat? or ?enhanc? or ?increas?)
L11         161 L10 AND (POTENTIAT? OR ?ENHANC? OR ?INCREAS?)

=> s l11 and (gemcitabine or antimetabolite)
L12           0 L11 AND (GEMCITABINE OR ANTIMETABOLITE)

=> d his

     (FILE 'HOME' ENTERED AT 16:10:32 ON 19 OCT 2009)

     FILE 'REGISTRY' ENTERED AT 16:10:45 ON 19 OCT 2009
L1             3 S DMXAA
L2            11 S GEMCITABINE

     FILE 'CAPLUS' ENTERED AT 16:11:09 ON 19 OCT 2009
L3           197 S L1
L4          5378 S L2
L5             6 S L1 AND L2
L6             6 DUP REM L5 (0 DUPLICATES REMOVED)

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:12:08 ON 19 OCT 2009

     FILE 'REGISTRY' ENTERED AT 16:12:14 ON 19 OCT 2009
                 SET SMARTSELECT ON
L7            SEL L1 1- CHEM :      12 TERMS
                 SET SMARTSELECT OFF
```

```
     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:12:14 ON 19 OCT 2009
L8          661 S L7
L9          630 S L8 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)
L10         255 S L9 AND PD<20020903
L11         161 S L10 AND (POTENTIAT? OR ?ENHANC? OR ?INCREAS?)
L12           0 S L11 AND (GEMCITABINE OR ANTIMETABOLITE)

=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       3.61      58.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.92

STN INTERNATIONAL LOGOFF AT 16:14:36 ON 19 OCT 2009
```